GlassScriptPhysician profile
Ammar Ghanem
NPI 1528026424
$6,476.12
in general payments reported to CMS, 2019-2025
35 companies · $628 in 2025
The $628 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,559 · 2020: $540 · 2021: $822 · 2022: $1,883 · 2023: $205 · 2024: $839 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $1,156.09 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $1,012.98 | 2019-2025 | Airsupra, Breztri |
| Veran Medical Technologies, INC. | $865.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $570.15 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $477.82 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $297.16 | 2020-2025 | |
| Mylan Specialty L.P. | $297.04 | 2019-2024 | Yupelri |
| Harmony Biosciences LLC | $252.52 | 2021-2024 | |
| Insmed, INC. | $221.29 | 2019-2025 | Arikayce, Brinsupri |
| Philips North America LLC | $151.36 | 2019-2022 | |
| Genentech USA, INC. | $139.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $109.25 | 2019 | |
| Resmed Corp | $85.92 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $84.94 | 2020-2022 | |
| Baxter Healthcare | $83.62 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $75.05 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.36 | 2020-2021 | |
| Electromed, INC. | $57.14 | 2021-2024 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $48.54 | 2021 | |
| Sunovion Pharmaceuticals INC. | $42.03 | 2021 | |
| Grifols USA, LLC | $39.94 | 2020-2025 | Prolastin-C Liquid |
| Mallinckrodt Enterprises LLC | $35.93 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $33.88 | 2025 | Lumryz |
| Abbvie INC. | $33.05 | 2024 | |
| Paratek Pharmaceuticals, INC. | $32.42 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $31.70 | 2024-2025 | Opsumit |
| Vifor Pharma, INC. | $26.19 | 2024 | Zemaira |
| Shire North American Group INC | $24.12 | 2019 | |
| Inogen, INC. | $22.88 | 2024 | |
| United Therapeutics Corporation | $22.71 | 2021 | |
| Axsome Therapeutics, INC. | $21.05 | 2025 | Sunosi |
| Viatris Specialty LLC | $17.31 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $15.14 | 2020 | |
| Novo Nordisk INC | $13.01 | 2022 | |
| Penumbra, INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammar Ghanem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.